[{"address1": "21 Ha\u2019arba\u2019a Street", "city": "Tel Aviv", "zip": "6473921", "country": "Israel", "phone": "972 3 541 3131", "fax": "972 3 541 3144", "website": "https://www.redhillbio.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.", "fullTimeEmployees": 53, "companyOfficers": [{"maxAge": 1, "name": "Mr. Dror  Ben-Asher", "age": 57, "title": "Co-Founder, Chairman & CEO", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 594612, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Razi  Ingber", "age": 39, "title": "Chief Financial Officer", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 339819, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gilead  Raday MPhil, MSc", "age": 48, "title": "Chief Operating Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 365556, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adi  Frish", "age": 53, "title": "Chief Corporate & Business Development Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 339300, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rick D. Scruggs", "age": 63, "title": "Chief Commercial Officer, President of RedHill Biopharma Inc. & Director", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 469802, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alexandra  Okmian", "title": "Senior Business Development & Investor Relations Manager", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Reza  Fathi Ph.D.", "age": 68, "title": "Senior Vice President of Research & Development", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 299291, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Guy  Goldberg J.D.", "age": 47, "title": "Chief Business Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 338126, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. June S. Almenoff FACP, M.D., Ph.D.", "age": 66, "title": "Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Patricia  Anderson B.Sc. RAC", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.452, "open": 0.44, "dayLow": 0.4312, "dayHigh": 0.45, "regularMarketPreviousClose": 0.452, "regularMarketOpen": 0.44, "regularMarketDayLow": 0.4312, "regularMarketDayHigh": 0.45, "beta": 3.461, "trailingPE": 0.1106, "forwardPE": 14.746667, "volume": 83164, "regularMarketVolume": 83164, "averageVolume": 1186038, "averageVolume10days": 448300, "averageDailyVolume10Day": 448300, "bid": 0.308, "ask": 0.572, "bidSize": 200, "askSize": 200, "marketCap": 14097961, "fiftyTwoWeekLow": 0.257, "fiftyTwoWeekHigh": 3.28, "priceToSalesTrailing12Months": 2.1589527, "fiftyDayAverage": 0.51816, "twoHundredDayAverage": 0.82339, "currency": "USD", "enterpriseValue": 3477227008, "profitMargins": 3.6624799, "floatShares": 7419225406, "sharesOutstanding": 31867000, "sharesShort": 906879, "sharesShortPriorMonth": 376153, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.0305, "heldPercentInstitutions": 0.062470004, "shortRatio": 1.12, "shortPercentOfFloat": 0.0306, "bookValue": 0.105, "priceToBook": 4.2133336, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": 23916000, "trailingEps": 4.0, "forwardEps": 0.03, "enterpriseToRevenue": 532.5, "enterpriseToEbitda": -156.957, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "RDHL", "underlyingSymbol": "RDHL", "shortName": "Redhill Biopharma Ltd.", "longName": "RedHill Biopharma Ltd.", "firstTradeDateEpochUtc": 1357569000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "55b47776-7c51-3ec7-bc27-c300c5d6081d", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.4424, "targetHighPrice": 760.0, "targetLowPrice": 760.0, "targetMeanPrice": 760.0, "targetMedianPrice": 760.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 5569000, "totalCashPerShare": 0.001, "ebitda": -22154000, "totalDebt": 1173000, "quickRatio": 0.46, "currentRatio": 0.839, "totalRevenue": 6530000, "debtToEquity": 56.694, "revenuePerShare": 1.008, "returnOnAssets": -0.15713, "freeCashflow": -18231876, "operatingCashflow": -35820000, "revenueGrowth": -0.956, "grossMargins": 0.47029, "operatingMargins": -10.607929, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-23"}]